Minocycline Corrects Early, Pre-plaque Neuroinflammation and Inhibits BACE-1 in a Transgenic Model of Alzheimer's Disease-like Amyloid Pathology
Overview
Affiliations
Background: A growing body of evidence indicates that inflammation is one of the earliest neuropathological events in Alzheimer's disease. Accordingly, we have recently shown the occurrence of an early, pro-inflammatory reaction in the hippocampus of young, three-month-old transgenic McGill-Thy1-APP mice in the absence of amyloid plaques but associated with intracellular accumulation of amyloid beta petide oligomers. The role of such a pro-inflammatory process in the progression of the pathology remained to be elucidated.
Methods And Results: To clarify this we administered minocycline, a tetracyclic derivative with anti-inflammatory and neuroprotective properties, to young, pre-plaque McGill-Thy1-APP mice for one month. The treatment ended at the age of three months, when the mice were still devoid of plaques. Minocycline treatment corrected the up-regulation of inducible nitric oxide synthase and cyclooxygenase-2 observed in young transgenic placebo mice. Furthermore, the down-regulation of inflammatory markers correlated with a reduction in amyloid precursor protein levels and amyloid precursor protein-related products. Beta-site amyloid precursor protein cleaving enzyme 1 activity and levels were found to be up-regulated in transgenic placebo mice, while minocycline treatment restored these levels to normality. The anti-inflammatory and beta-secretase 1 effects could be partly explained by the inhibition of the nuclear factor kappa B pathway.
Conclusions: Our study suggests that the pharmacological modulation of neuroinflammation might represent a promising approach for preventing or delaying the development of Alzheimer's disease neuropathology at its initial, pre-clinical stages. The results open new vistas to the interplay between inflammation and amyloid pathology.
Saxena S, Ansari S, Maurya V, Kumar S, Sharma D, Malhotra H ACS Pharmacol Transl Sci. 2024; 7(12):3645-3657.
PMID: 39698259 PMC: 11651204. DOI: 10.1021/acsptsci.4c00400.
Patwekar M, Patwekar F, Khan S, Sharma R, Kumar D Curr Top Med Chem. 2024; 24(19):1665-1682.
PMID: 38644708 DOI: 10.2174/0115680266295495240415114919.
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.
Garmendia J, De Sanctis C, Das V, Annadurai N, Hajduch M, De Sanctis J Curr Neuropharmacol. 2023; 22(6):1080-1109.
PMID: 37898823 PMC: 10964103. DOI: 10.2174/1570159X22666231017141636.
NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer's Disease.
Sivamaruthi B, Raghani N, Chorawala M, Bhattacharya S, Prajapati B, Elossaily G Biomedicines. 2023; 11(9).
PMID: 37761028 PMC: 10526355. DOI: 10.3390/biomedicines11092587.
Advances in the study of the molecular biological mechanisms of radiation-induced brain injury.
Gan C, Li W, Xu J, Pang L, Tang L, Yu S Am J Cancer Res. 2023; 13(8):3275-3299.
PMID: 37693137 PMC: 10492106.